Your ILCA Agenda: Events & activities to look out for before the end of June
Here is a selection of the upcoming activities, events and applications open at ILCA that we thought might [...]
Read moreLiver cancer understaging in liver transplantation in the current era of radiologic imaging and newer generation locoregional therapies
Background: Discordance in hepatocellular carcinoma (HCC) staging between pre-transplant imaging and [...]
Read moreThe Role of Interferon Regulatory Factors in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
Non-alcoholic fatty liver disease (NAFLD) is becoming the most common chronic liver disease with many [...]
Read more
Join us in Paris for the inaugural Single Topic Workshop: HCC Risk Stratification and Surveillance
Less than 2 months until ILCA’s inaugural Single Topic Workshop (STW) and all the speakers have been [...]
Read more
#ILCA22 Abstracts Deadline Extended
Don’t miss the opportunity, there’s still time to submit your work We know Mondays are hard, so [...]
Read moreRole of locoregional therapies in the management of patients with hepatocellular carcinoma
Hepatocellular carcinoma (HCC) was the sixth most common cancer and the third cause of cancer-related [...]
Read moreHepatocellular carcinoma on the background of nonalcoholic fatty liver disease: epidemiological update
The epidemiological features of hepatocellular carcinoma have changed significantly in the last decades. [...]
Read moreSafety and efficacy of DEM-TACE performed with drug-eluting microspheres smaller than 300 μm in patients with HCC and TIPS
Aim: Safety and efficacy evidence of drug-eluting-microspheres trans-arterial chemoembolization (DEM-TACE) [...]
Read more